Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), poses a significant public health concern [1]. It stands as the primary cause of morbidity and mortality among hospitalized patients. Previously, all patients were admitted to the hospital, resulting in an average hospitalization cost of $37,352 US dollars in 2015, in order to obtain decreased survival rates [1]. However, the introduction of oral therapeutic options has created possibilities for safe outpatient management [2].
